Business Standard

Sun Pharma posts net loss of Rs 2,277 cr in Q4, declares Rs 3 dividend

Sun Pharma's consolidated revenue rose 10% to Rs 9,446 cr in Q4FY22

Sun Pharma
Premium

BS Web Team New Delhi
Pharma major Sun Pharma on Monday reported a surprise consolidated net loss of Rs 2,277 crore for the quarter ending March 31, 2022. It reported consolidated net profit of Rs 848 crore in the year-ago period.

Total loss cited as an exceptional item during the fourth quarter, stood at Rs 3,936 crore. During the quarter and year ended March 2022, the company said its unit Taro Pharmaceutical Industries has acquired Alchemee, formerly The Proactiv Company (TPC), from Galderma. Accordingly, the results for the quarter and year ended March 2022 are not comparable to the earlier periods presented, it added.

Sun Pharma's consolidated

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in